La vendita allo scoperto per Processa Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Processa Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Processa Pharmaceuticals (NASDAQ:PCSA) Azioni, Report sulle vendite allo scoperto

PROCESSA PHARMACEUTICALS INC

Processa Pharma

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals Inc

Fujitsu (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FJTSY#OTC">FJTSY</a>) reported quarterly earnings of $0.12 per share. This is a 1100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $5.188 billion which beat the analyst consensus estimate of $4.980 billion by 4.18 percent. This is a 2.59 percent decrease over sales of $5.326 billion the same period last year.

Earnings

Earnings Beats

News

FJTSY

Fujitsu Q1 Adj. EPS $0.12 Up From $0.01 YoY, Sales $5.188B Beat $4.980B Estimate

Baird analyst Timothy Wojs maintains Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) with a Outperform and lowers the price target from $85 to $84.

Price Target

Analyst Ratings

CARR

Baird Maintains Outperform on Carrier Global, Lowers Price Target to $84

Wells Fargo analyst Eric Luebchow maintains American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) with a Overweight and lowers the price target from $240 to $230.

Wells Fargo Maintains Overweight on American Tower, Lowers Price Target to $230

Macro Economic Events

Politics

Global

Economics

General

INDA

Reuters Reports White House's Hassett Speaking On India Trade, Says Trump Is Frustrated With Progress; Trump Thinks Tariff Will Help Situation; Trump, Greer Will Have More Information On Additional Penalty Shortly; India Might Reconsider Their Practices; Speaking On China Trade, Says Trump To Be Briefed Today; Trump Will Probably Want Changes Before Agreement Announced

Baird analyst David Rescott maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform and raises the price target from $283 to $285.

Baird Maintains Outperform on Penumbra, Raises Price Target to $285

RBC Capital analyst Dan Bergstrom maintains CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) with a Sector Perform and raises the price target from $185 to $217.

CVLT

RBC Capital Maintains Sector Perform on CommVault Systems, Raises Price Target to $217

West Fraser Timber (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFG#NYSE">WFG</a>) has entered a no-action zone under the Adhishthana Principles, with both its weekly and monthly structures pointing to a prolonged period of consolidation. Here&#8217;s how the cycle is shaping up and why investors might want to steer clear for now.
<h3 class="wp-block-heading">West Fraser&#8217;s Guna Triads and the Slump</h3>
Under the Adhishthana Principles, phases 14, 15, and 16 are collectively referred to as the Guna Triads. These triads are key in determining whether a stock will attain its Nirvana in phase 18, which represents the highest point of the 18-phase cycle. For a Nirvana move to materialize, the triads must show the presence of Satoguna, which reflects a clean and strong bullish structure.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"A Lack of noticeable Satoguna in any of the triads leads to no Nirvana in Phase 18." -Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy
</blockquote>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="553" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/30104843/WFG-Stock-Weekly-Adhishthana-.png" alt="Fig.1 West Fraser Weekly Chart Guna Triads (Source: Adhishthana.com )" class="wp-image-16637" style="width:625px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/30104843/WFG-Stock-Weekly-Adhishthana-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/30104843/WFG-Stock-Weekly-Adhishthana--300x138.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/30104843/WFG-Stock-Weekly-Adhishthana--1024x472.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/30104843/WFG-Stock-Weekly-Adhishthana--768x354.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 West Fraser Weekly Chart Guna Triads (Source: Adhishthana.com )</figcaption></figure>
In the case of West Fraser, the triads lacked the presence of Satoguna. This rules out the possibility of a Nirvana move, setting the stage for continued bearishness in phase 18. This has already played out to a large extent. Since entering phase 18, the stock has corrected by around 29 percent and has remained in a slump for over 245 days.
Phase 18 on the weekly chart ends on 25 May 2026. Until then, further weakness or sideways movement is likely. The monthly chart supports a similar outlook.
<h3 class="wp-block-heading">Monthly Chart and the Upcoming No-Action Phase 4</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="792" height="416" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/30104935/WFG-Monthly-Chart-Adhishthana-.png" alt="Fig.2 West Fraser Monthly Chart (Source: Adhishthana.com )" class="wp-image-16638" style="width:592px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/30104935/WFG-Monthly-Chart-Adhishthana-.png 792w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/30104935/WFG-Monthly-Chart-Adhishthana--300x158.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/30104935/WFG-Monthly-Chart-Adhishthana--768x403.png 768w" sizes="(max-width: 792px) 100vw, 792px" /><figcaption class="wp-element-caption">Fig.2 West Fraser Monthly Chart (Source: Adhishthana.com )</figcaption></figure>
The stock is currently in phase 3 on the monthly chart and is forming the Adhishthana Yajya structure, which typically signals bearishness. This phase is set to end on 2 November 2025. After that, the stock will enter phase 4.
According to the principles, phase 4 is considered a no-action phase. This phase will last until late 2029, pointing to a multi-year period of consolidation and limited upside potential.
<h3 class="wp-block-heading">Investor Outlook</h3>
The combination of a Nirvana-devoid phase 18 on the weekly chart and the no-action phase 4 on the monthly chart suggests a prolonged phase of underperformance. Investors should avoid entering the stock at this time and wait until the structure begins to shift.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Equities

Technicals

Opinion

Signals

Trading Ideas

West Fraser Timber Stock May Face Prolonged Weakness Ahead

Wingstop Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) shares soared over 27% on Wednesday after the fast-casual restaurant chain reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46717593/wingstop-inc-reports-fiscal-second-quarter-financial-results" rel="noreferrer noopener">stronger-than-expected</a> second-quarter earnings and sales, while also boosting its full-year global unit growth forecast.
The company&#8217;s adjusted earnings per share of $1 beat analyst estimates of 86 cents, and quarterly sales of $174.33 million surpassed the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">Street&#8217;s $172.77 million view</a>, driven by franchise development and a rise in digital sales, which now account for 72.2% of total system-wide sales.
Royalty revenue, franchise fees and other increased&nbsp;$8.7 million, of which&nbsp;$9.8 million&nbsp;was due to net new franchise development, partially offset by a decrease of&nbsp;$1.4 million&nbsp;due to a 1.9% decline in domestic same-store sales.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/07/46720865/etsy-reports-mixed-q2-earnings-shares-move-higher" rel="noreferrer noopener">Etsy Reports Mixed Q2 Earnings, Shares Move Higher</a>
Quarterly adjusted EBITDA jumped to $59.21 million, higher than $51.78 million a year ago. In the second quarter, Wingstop reported a 13.9% increase in system-wide sales, reaching $1.3 billion compared to the same period in 2024.
Digital sales accounted for 72.2% of total system-wide sales, reflecting continued growth in the company&#8217;s digital ordering channels.
Average unit volume (AUV) for domestic restaurants rose to $2.1 million. However, domestic same-store sales declined by 1.9% year over year.
&#8220;Our momentum in development continued in the second quarter, opening 129 net new units, delivering 19.8% unit growth, which marked our fourth consecutive quarter of opening more than 100 net new units,&#8221; said&nbsp;Michael Skipworth, President and CEO.&nbsp;
&#8220;We continue to open new restaurants at a record pace, demonstrating our brand partners&#8217; commitment to growing the Wingstop brand, furthering us towards our vision of becoming a Top 10 Global Restaurant Brand,&#8221; he added.
As of June&nbsp;28, there were 2,818 Wingstop restaurants system-wide. This included 2,411 restaurants in&nbsp;the United States, of which 2,357 were franchised restaurants and 54 were company-owned, and 407 franchised restaurants were in international markets, including U.S. territories.
The company exited the quarter with cash and equivalents worth $227.94 million.
<h2 class="wp-block-heading">Dividend</h2>
On July&nbsp;29, the company approved an increase in the quarterly dividend payable to Wingstop stockholders from&nbsp;27 cents&nbsp;to&nbsp;30&nbsp;cents per share of common stock, resulting in a total dividend of approximately&nbsp;$8.4 million. This dividend will be paid on September&nbsp;5.
<h2 class="wp-block-heading">Outlook</h2>
Wingstop has updated its 2025 outlook, raising its global unit growth forecast to 17%-18% from the previous 16%-17% range and lowering its expected net interest expense to approximately $39 million, down from $40 million.
The company also reaffirmed its projection of about 1% growth in domestic same-store sales for the year.
Price Action: WING shares are trading higher by 27.4% to $367.67 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46720671/gsk-lifts-outlook-as-specialty-medicines-vaccines-fuel-growth" target="_blank" rel="noreferrer noopener">GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth</a></li>
</ul>
Image via Shutterstock

Guidance

Markets

Movers

WING

Wingstop Unveils Bold Expansion Plans, Eyes Top Global Brand Status

Wells Fargo analyst Michael Sison maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Equal-Weight and lowers the price target from $22 to $21.

Wells Fargo Maintains Equal-Weight on Olin, Lowers Price Target to $21

<a href="https://x.com/nuburulasers/status/1950557420184301955" title="https://x.com/nuburulasers/status/1950557420184301955">https://x.com/nuburulasers/status/1950557420184301955</a>

BURU

NUBURU Posts On X "Important Update from NUBURU. With up to $100M in capital firepower, NYSE listing compliance secured & transformational @TekneGroup acquisition news on the way as we are entering a new era. ..."

RBC Capital analyst Matthew McKellar maintains Clearwater Paper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) with a Outperform and lowers the price target from $37 to $36.

RBC Capital Maintains Outperform on Clearwater Paper, Lowers Price Target to $36

Wells Fargo analyst Christian Wetherbee maintains Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) with a Underweight and raises the price target from $24 to $25.

WERN

Wells Fargo Maintains Underweight on Werner Enterprises, Raises Price Target to $25

Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Neutral and raises the price target from $15 to $17.

BBNX

Baird Maintains Neutral on Beta Bionics, Raises Price Target to $17

Wells Fargo analyst Christian Wetherbee maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Equal-Weight and lowers the price target from $98 to $91.

Wells Fargo Maintains Equal-Weight on United Parcel Service, Lowers Price Target to $91

Wells Fargo analyst Kosta Tasoulis maintains Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with a Equal-Weight and raises the price target from $30 to $33.

Wells Fargo Maintains Equal-Weight on Sensata Technologies, Raises Price Target to $33

Baird analyst Mark Altschwager maintains Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) with a Outperform and raises the price target from $24 to $30.

WRBY

Baird Maintains Outperform on Warby Parker, Raises Price Target to $30

Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) will release earnings results for the fourth quarter, after the <a href="https://www.benzinga.com/quote/msft/earnings">closing bell on Wednesday, July 30.</a>
Analysts expect the Redmond, Washington-based company to report quarterly earnings at $3.38 per share, up from $2.95 per share in the year-ago period. Microsoft projects to report quarterly revenue at $73.83 billion, compared to $64.73 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The company has beaten analyst estimates for revenue in nine straight quarters.
Microsoft shares rose 0.01% to close at $512.57 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/msft/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Stifel analyst Brad Reback maintained a Buy rating and increased the price target from $500 to $550 on July 28, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Wedbush analyst Daniel Ives reiterated an Outperform with a price target of $600 on July 25, 2025. This analyst has an accuracy rate of 81%.</li>
<li>Evercore ISI Group analyst Kirk Materne maintained an Outperform rating and increased the price target from $515 to $545 on July 25, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Loop Capital analyst Yun Kim maintained a Buy rating and raised the price target from $550 to $600 on July 24, 2025. This analyst has an accuracy rate of 77%.</li>
<li>UBS analyst Karl Keirstead maintained a Buy rating and increased the price target from $500 to $600 on July 23, 2025. This analyst has an accuracy rate of 78%.</li>
</ul>
Considering buying MSFT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30041947/image-471-1024x586.png" alt="" class="wp-image-1006580" style="width:655px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30041947/image-471-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30041947/image-471-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30041947/image-471-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30041947/image-471.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46684052/jim-cramer-prefers-this-financial-stock-over-brighthouse-financial">Jim Cramer Prefers This Financial Stock Over Brighthouse Financial</a></li>
</ul>
Photo via Shutterstock

MSFT

Microsoft Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

adidas (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADDYY#OTC">ADDYY</a>) reported quarterly earnings of $1.15 per share which missed the analyst consensus estimate of $1.90 by 39.47 percent. This is a 94.92 percent increase over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $6.75 billion which beat the analyst consensus estimate of $6.24 billion by 8.06 percent. This is a 7.35 percent increase over sales of $6.29 billion the same period last year.

Earnings Misses

ADDYY

adidas Q2 EPS $1.15 Misses $1.90 Estimate, Sales $6.75B Beat $6.24B Estimate

U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining around 0.1% on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.06% to 44,660.57 while the NASDAQ rose 0.19% to 21,138.92. The S&amp;P 500 also rose, gaining, 0.10% to 6,377.27.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46718035/cramer-says-no-to-this-auto-parts-provider-yes-another">Jim Cramer Says &#8216;No&#8217; To This Auto Parts Provider, But &#8216;Yes&#8217; To Another</a>
Leading and Lagging Sectors Utilities shares jumped by 0.7% on Wednesday.
In trading on Tuesday, energy stocks dipped by 0.7%.
Top Headline
Kraft Heinz Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) reported better-than-expected earnings for the second quarter on Wednesday.
The company posted quarterly earnings of 69 cents per share which beat the analyst consensus estimate of 64 cents per share. The company reported quarterly sales of $6.352 billion which beat the analyst consensus estimate of $6.261 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Replimune Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares shot up 62% to $6.09 after gaining 18% on Tuesday.</li>
<li>Shares of BioNexus Gene Lab Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) got a boost, surging 59% to $7.10 after the company and Fidelion signed a term sheet.</li>
<li>Rocky Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) shares were also up, gaining 27% to $29.24 after the company announced better-than-expected quarterly earnings.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Vyne Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) shares dropped 72% to $0.41 after the company announced that Phase 2b trial with Repibresib Gel in nonsegmental vitiligo did not meet primary endpoint or key secondary endpoint of F-VASI50 and F-VASI75.</li>
<li>Shares of Sos Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOS#NASDAQ">SOS</a>) were down 50% to $3.03 after the company announced the pricing of $7.5 million registered direct offering.</li>
<li>Pheton Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) was down, falling 44% to $0.92.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $69.60 while gold traded up 1% at $3,356.50.
Silver traded up 1.2% to $37.810 on Wednesday, while copper fell 0.6% to $5.5935.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.1%, while Spain's IBEX 35 Index gained 0.1%. London's FTSE 100 fell 0.1%, Germany's DAX 40 gained 0.3% and France's CAC 40 rose 0.5% during the session.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 falling 0.05%, Hong Kong's Hang Seng falling 1.36%, China's Shanghai Composite rising 0.17% and India's BSE Sensex gaining 0.18%.
Economics
<ul class="wp-block-list">
<li>U.S. pending home sales declined by 0.8% from the previous month in May following a 1.8% gain in April.</li>
<li>The U.S. economy expanded at an annualized rate of 3% in the second quarter following a 0.5% contraction in the previous quarter.</li>
<li>Private businesses in the U.S. added 104,000 jobs in July, compared to market estimates of a 75,000 increase.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46718502/how-to-earn-500-a-month-from-meta-platforms-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Meta Platforms Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

Eurozone

Commodities

Intraday Update

BGLC

PTHL

RCKY

REPL

VYNE

US Stocks Edge Higher; Kraft Heinz Earnings Top Views

Baird analyst David Tarantino maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Neutral and raises the price target from $88 to $100.

SBUX

Baird Maintains Neutral on Starbucks, Raises Price Target to $100

Press Releases

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Peraso Inc (NASDAQ: PRSO) Deploys Stealth Tech Shipment for Military Use – Tapping $500M NATO Market – More Stocks Inside

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Processa Pharmaceuticals Provides Portfolio and Business Update

BGSF

CERO

INEO

PCSA

PNPNF

PRPH

PRSO

SAFX

SNYR

TSXV:PNPN

XTIA

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Akanda

Artelo Biosciences

Biofrontera

CNS Pharma

China Pharma Holding

Enveric Biosciences

Evoke Pharma

Impact BioMedical

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

Talphera

TNF Pharmaceuticals

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Comments

Processa Pharmaceuticals

Vendite allo scoperto

Processa Pharmaceuticals (NASDAQ:PCSA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO